מדינה: הממלכה המאוחדת
שפה: אנגלית
מקור: MHRA (Medicines & Healthcare Products Regulatory Agency)
Propiverine hydrochloride
Consilient Health Ltd
G04BD06
Propiverine hydrochloride
45mg
Modified-release capsule
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 07040200; GTIN: 5060064171943
OBJECT 1 DETRUNORM XL 45 MG MODIFIED-RELEASE CAPSULES Summary of Product Characteristics Updated 12-Dec-2014 | Concordia International - formerly AMCo 1. Name of the medicinal product Detrunorm XL 45 mg Modified-Release Capsules 2. Qualitative and quantitative composition Each capsule contains 45 mg propiverine hydrochloride (equivalent to 40.92 mg propiverine). Excipients: Lactose monohydrate (8.5 mg), for a full list of excipients, see section 6.1 3. Pharmaceutical form Modified-release capsule, hard Orange size 2 capsules containing white to off-white pellets. 4. Clinical particulars 4.1 Therapeutic indications Symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder syndrome or neurogenic detrusor overactivity (detrusor hyperreflexia) from spinal cord injuries. 4.2 Posology and method of administration Capsules for oral use. Do not crush or chew the capsules. The recommended daily doses are as follows: Adults: One capsule (= 45 mg propiverine hydrochloride) once daily. As a standard treatment, one modified-release capsule Detrunorm XL 30 mg once a day or one tablet of Detrunorm (= 15 mg propiverine hydrochloride) twice a day is recommended, this may be increased to one tablet of Detrunorm (= 15 mg propiverine hydrochloride) three times a day. Some patients may already respond to a dosage of 15 mg propiverine hydrochloride a day. In patients whom Detrunorm (= 15 mg propiverine hydrochloride) tablet three times daily is indicated, the 15 mg tablet three times daily regimen could be replaced by Detrunorm XL 45 mg Modified-Release Capsules once a day. The maximum daily dose is one Detrunorm XL 45 mg Modified-Release Capsule daily. Elderly: Generally there is no special dosage regimen for the elderly (see section 5.2). Paediatric population: Due to a lack of data, this product should not be used in children. Caution should be exercised and clinicians should monitor patients carefully for side effects in the following dispositions (see sections קרא את המסמך השלם